Infectious Disease Diagnostics Global Market - Forecast to 2027
Infectious Disease Diagnostics (IDD) comprises of various diagnostics technologies and platforms used by healthcare professionals to detect and diagnose infectious diseases causing pathogens in human samples, including blood, serum, throat swabs, urine, and stool. It enables healthcare professionals for early diagnosis of the diseases and serves the patient population with better care management in less time and cost. With growing technological advancements, the IDD platforms are increasingly becoming more useful to serve the patients with a more convenient, faster, and highly accurate diagnosis. It helps the end-users to provide a cost-effective diagnostics process to the patient population.
An estimated by IQ4I Research, the Infectious Disease Diagnostics global market is expected to reach $26,028.0 million by 2027 growing at a low single digit CAGR from 2020 to 2027. Some of the factors such as the increasing prevalence of infectious diseases, the requirement of early detection for infectious disease, increasing point of care diagnostics and rapid diagnostics, favorable reimbursements, technological advancements and rising investments in diagnostics.
The Infectious Disease Diagnostics market based on product is segmented into consumables, instruments, and software & services. The consumables segment accounted for the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.
The Infectious Disease Diagnostics market based on technology is segmented into molecular diagnostics, immunodiagnostics, and others (mass spectroscopy, culture media). Among these, the immunodiagnostics segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The molecular diagnostics segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the increasing prevalence of infectious diseases and technological advancements.
IDD Molecular diagnostics global market based on product type, it is segmented into PCR, INAAT, Microarray, NGS, ISH, and others. Among these, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious disease, technological advancements and rise in the number of diagnostic centers and hospitals. The NGS segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the advancements and declining costs of NGS platforms and improving regulatory and reimbursement scenario for NGS based diagnostic tests.
IDD Immunodiagnostics global market based on product type, it is segmented into CHLIA, Lateral flow Immunochromatography assay (LFIA), Enzyme Immunoassay (EIA), Fluorescent Immunoassay (FIA) and others. Among these, the LFIA segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious diseases, increase in demand for home-based lateral flow assay test kits and surge in demand for point-of-care testing. The EIA segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the increasing incidence of infectious diseases and increasing demand for cost-effective EIA test kits for diagnosis for various infectious diseases.
Infectious Disease Diagnostics global market based on application is segmented into a bacterial infection, viral infection, fungal infection, and other infections. Among these applications, viral infection diagnostics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to rising prevalence of HIV, hepatitis, influenza, rubella, increasing demand for more rapid diagnostic test kits for influenza and rising adoption of diagnostic kits for viral infections by physicians.
Bacterial infection diagnostics global market based on application type, it is segmented into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus Aureus holds the largest in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Tuberculosis segment is the fastest-growing growing at a strong mid single digit CAGR from 2020 to 2027.
Viral infection diagnostics global market based on application type, it is segmented into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and others. Among these, HIV-1 holds the largest revenue in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027.
Fungal infection diagnostics global market based on application type, it is segmented into Candida, Aspergillus, and others. Among these, Candida holds the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.
Other infections diagnostics global market based on application type, it is segmented into Malaria, Trichomonas vaginalis, and others. Among these, Trichomonas Vaginalis holds the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Malaria segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.
Infectious Disease Diagnostics global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) & clinics, centralized laboratory & clinical trials, academics & research institutes, and others (home care, self-test and blood banks). Among end-users, the hospitals, ASCs & clinics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Centralized Laboratories segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.
Infectious Disease Diagnostics global market based on the mode of the test is segmented into centralized laboratories and Point-of-care (POC). Among these, the centralized laboratories segment holds the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The POC segment holds the second largest revenue in 2020 due to the rising prevalence of infectious diseases, technological advancements in POC testing products and growing patient awareness of POC testing are some of the major factors driving the POC market.
Infectious Disease Diagnostics market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, Japan, India and Rest of APAC) and Rest of the world (Brazil, Rest of LATAM and the Middle East & Africa). North America holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the adoption of the technological advancements, presence of a highly developed healthcare system, increasing incidence of infectious diseases, the presence of a large number of leading national clinical laboratories, increasing reimbursement scheme by the government, product launches, skilled personnel, investments, and funds. The Asia-Pacific region is the fastest-growing region growing with a strong mid single digit CAGR from 2020 to 2027 due to the increasing healthcare awareness, increasing prevalence of influenza, malaria and TB, government funding in developing countries.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
An estimated by IQ4I Research, the Infectious Disease Diagnostics global market is expected to reach $26,028.0 million by 2027 growing at a low single digit CAGR from 2020 to 2027. Some of the factors such as the increasing prevalence of infectious diseases, the requirement of early detection for infectious disease, increasing point of care diagnostics and rapid diagnostics, favorable reimbursements, technological advancements and rising investments in diagnostics.
The Infectious Disease Diagnostics market based on product is segmented into consumables, instruments, and software & services. The consumables segment accounted for the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.
The Infectious Disease Diagnostics market based on technology is segmented into molecular diagnostics, immunodiagnostics, and others (mass spectroscopy, culture media). Among these, the immunodiagnostics segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The molecular diagnostics segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the increasing prevalence of infectious diseases and technological advancements.
IDD Molecular diagnostics global market based on product type, it is segmented into PCR, INAAT, Microarray, NGS, ISH, and others. Among these, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious disease, technological advancements and rise in the number of diagnostic centers and hospitals. The NGS segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the advancements and declining costs of NGS platforms and improving regulatory and reimbursement scenario for NGS based diagnostic tests.
IDD Immunodiagnostics global market based on product type, it is segmented into CHLIA, Lateral flow Immunochromatography assay (LFIA), Enzyme Immunoassay (EIA), Fluorescent Immunoassay (FIA) and others. Among these, the LFIA segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious diseases, increase in demand for home-based lateral flow assay test kits and surge in demand for point-of-care testing. The EIA segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the increasing incidence of infectious diseases and increasing demand for cost-effective EIA test kits for diagnosis for various infectious diseases.
Infectious Disease Diagnostics global market based on application is segmented into a bacterial infection, viral infection, fungal infection, and other infections. Among these applications, viral infection diagnostics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to rising prevalence of HIV, hepatitis, influenza, rubella, increasing demand for more rapid diagnostic test kits for influenza and rising adoption of diagnostic kits for viral infections by physicians.
Bacterial infection diagnostics global market based on application type, it is segmented into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus Aureus holds the largest in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Tuberculosis segment is the fastest-growing growing at a strong mid single digit CAGR from 2020 to 2027.
Viral infection diagnostics global market based on application type, it is segmented into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and others. Among these, HIV-1 holds the largest revenue in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027.
Fungal infection diagnostics global market based on application type, it is segmented into Candida, Aspergillus, and others. Among these, Candida holds the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.
Other infections diagnostics global market based on application type, it is segmented into Malaria, Trichomonas vaginalis, and others. Among these, Trichomonas Vaginalis holds the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Malaria segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.
Infectious Disease Diagnostics global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) & clinics, centralized laboratory & clinical trials, academics & research institutes, and others (home care, self-test and blood banks). Among end-users, the hospitals, ASCs & clinics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Centralized Laboratories segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.
Infectious Disease Diagnostics global market based on the mode of the test is segmented into centralized laboratories and Point-of-care (POC). Among these, the centralized laboratories segment holds the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The POC segment holds the second largest revenue in 2020 due to the rising prevalence of infectious diseases, technological advancements in POC testing products and growing patient awareness of POC testing are some of the major factors driving the POC market.
Infectious Disease Diagnostics market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, Japan, India and Rest of APAC) and Rest of the world (Brazil, Rest of LATAM and the Middle East & Africa). North America holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the adoption of the technological advancements, presence of a highly developed healthcare system, increasing incidence of infectious diseases, the presence of a large number of leading national clinical laboratories, increasing reimbursement scheme by the government, product launches, skilled personnel, investments, and funds. The Asia-Pacific region is the fastest-growing region growing with a strong mid single digit CAGR from 2020 to 2027 due to the increasing healthcare awareness, increasing prevalence of influenza, malaria and TB, government funding in developing countries.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Indian
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of LATAM
- Middle East and Africa
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing prevalence of infectious diseases
3.3.1.2 Requirement of early detection of infectious disease
3.3.1.3 Increasing point of care diagnostics and rapid diagnostics
3.3.1.4 Favorable reimbursements
3.3.1.5 Technological advancements
3.3.1.6 Rising investments in infectious disease diagnostics
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Lack of skilled professionals
3.3.2.2 The high cost of infectious disease diagnostic technologies and tests
3.3.2.3 Lack of reproducibility and repeatability
3.3.2.4 Stringent regulatory guidelines
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 quality management system
3.4.1.1 ISO 16256: 2012 clinical laboratory testing and in vitro diagnostic test systems
3.4.1.2 ISO /TS 16782: 2016 clinical laboratory testing
3.4.1.3 ISO/TS 17518: 2015 medical laboratories- reagents for staining biological material
3.4.1.4 ISO20776-1:2019 susceptibility testing of infectious agents and evaluation of the performance of antimicrobial susceptibility test device
3.4.2 U.S.
3.4.3 EUROPE
3.4.4 CHINA
3.4.5 INDIA
3.4.6 JAPAN
3.4.7 SOUTH KOREA
3.5 TECHNOLOGICAL ADVANCEMENTS
3.5.1 NANOTRAP VIRUS CAPTURE KIT
3.5.2 RNASCOPE CHROMOGENIC ASSAYS
3.5.3 NEXT-GENERATION SEQUENCING (NGS)
3.5.4 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP)
3.5.5 PORTABLE DNA SEQUENCER
3.5.6 NANOPIN DIAGNOSTIC PLATFORM
3.5.7 LUMINEX XMAP TECHNOLOGY
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 BARGAINING POWER OF SUPPLIERS
3.6.4 BARGAINING POWER OF BUYERS
3.6.5 COMPETITIVE RIVALRY
3.7 SUPPLY CHAIN ANALYSIS
3.8 REIMBURSEMENT SCENARIO
3.9 FUNDING SCENARIO
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10.1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.2 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.3 IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.4 POINT OF CARE (POC) DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.11 CORONAVIRUS (COVID-19)
3.12 FDA-EUA APPROVED DIAGNOSTICS TESTS
3.13 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TRANSMISSION
3.14 INFECTIOUS DISEASE DIAGNOSTICS COMPANY COMPARISON TABLE BY APPLICATION, SOURCE, TECHNOLOGY
4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 CONSUMABLES
4.3 INSTRUMENTS
4.4 SOFTWARE & SERVICES
5 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 IDD MOLECULAR DIAGNOSTICS
5.2.1 POLYMERASE CHAIN REACTION (PCR)
5.2.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
5.2.3 MICROARRAY
5.2.4 NEXT-GENERATION SEQUENCING (NGS)
5.2.5 IN-SITU HYBRIDIZATION (ISH)
5.2.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
5.3 IDD IMMUNO DIAGNOSTICS
5.3.1 CHEMILUMINESCENCE IMMUNOASSAY (CHLIA)
5.3.2 LATERAL FLOW IMMUNOCHROMATOGRAPHY ASSAY (LFIA)
5.3.3 ENZYME IMMUNOASSAY (EIA)
5.3.4 FLUORESCENT IMMUNOASSAY (FIA)
5.3.5 OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES
5.4 IDD OTHER DIAGNOSTICS
6 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 BACTERIAL INFECTION
6.2.1 TREPONEMA PALLIDUM
6.2.2 GARDNERELLA VAGINALIS
6.2.3 STAPHYLOCOCCUS AUREUS
6.2.4 CLOSTRIDIUM DIFFICILE
6.2.5 STREPTOCOCCUS (A & B)
6.2.6 METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
6.2.7 CHLAMYDIA TRACHOMATIS (CT) AND NEISSERIA GONORRHOEAE (NG)
6.2.8 TUBERCULOSIS (TB)
6.2.9 OTHER BACTERIAL INFECTION
6.3 VIRAL INFECTION
6.3.1 HIV-1
6.3.2 INFLUENZA
6.3.3 DENGUE
6.3.4 HEPATITIS B
6.3.5 HEPATITIS C
6.3.6 HUMAN PAPILLOMAVIRUS (HPV)
6.3.7 HERPES SIMPLEX VIRUS (HSV)
6.3.8 ZIKA VIRUS
6.3.9 OTHER VIRAL INFECTION
6.4 FUNGAL INFECTION
6.4.1 CANDIDA
6.4.2 ASPERGILLUS
6.4.3 OTHER FUNGAL INFECTION
6.5 OTHER INFECTION
6.5.1 MALARIA
6.5.2 TRICHOMONAS VAGINALIS
6.5.3 OTHER INFECTIONS
7 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY END-USER
7.1 INTRODUCTION
7.2 HOSPITAL, AMBULATORY SURGICAL CENTERS (ASCS) & CLINICS
7.3 CENTRALIZED LABORATORIES AND CLINICAL TRIALS
7.4 ACADEMICS AND RESEARCH INSTITUTES
7.5 OTHER END-USERS
8 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TESTING
8.1 INTRODUCTION
8.2 CENTRALIZED LABORATORIES
8.3 POINT OF CARE
9 REGIONAL ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 REST OF NORTH AMERICA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 ITALY
9.3.4 REST OF EUROPE
9.4 APAC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF APAC
9.5 ROW
9.5.1 BRAZIL
9.5.2 REST OF LATAM
9.5.3 MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 PRODUCT APPROVAL
10.3 NEW PRODUCT LAUNCH
10.4 OTHERS
11 MAJOR COMPANIES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BECTON, DICKINSON AND COMPANY
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIOMERIEUX SA
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 BIO-RAD LABORATORIES, INC.
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 DANAHER CORPORATION
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 F. HOFFMANN-LA ROCHE LTD
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 HOLOGIC, INC.
11.7.1 COVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 QIAGEN N.V.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 SIEMENS HEALTHINEERS GMBH
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 THERMO FISHER SCIENTIFIC INC.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing prevalence of infectious diseases
3.3.1.2 Requirement of early detection of infectious disease
3.3.1.3 Increasing point of care diagnostics and rapid diagnostics
3.3.1.4 Favorable reimbursements
3.3.1.5 Technological advancements
3.3.1.6 Rising investments in infectious disease diagnostics
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Lack of skilled professionals
3.3.2.2 The high cost of infectious disease diagnostic technologies and tests
3.3.2.3 Lack of reproducibility and repeatability
3.3.2.4 Stringent regulatory guidelines
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 quality management system
3.4.1.1 ISO 16256: 2012 clinical laboratory testing and in vitro diagnostic test systems
3.4.1.2 ISO /TS 16782: 2016 clinical laboratory testing
3.4.1.3 ISO/TS 17518: 2015 medical laboratories- reagents for staining biological material
3.4.1.4 ISO20776-1:2019 susceptibility testing of infectious agents and evaluation of the performance of antimicrobial susceptibility test device
3.4.2 U.S.
3.4.3 EUROPE
3.4.4 CHINA
3.4.5 INDIA
3.4.6 JAPAN
3.4.7 SOUTH KOREA
3.5 TECHNOLOGICAL ADVANCEMENTS
3.5.1 NANOTRAP VIRUS CAPTURE KIT
3.5.2 RNASCOPE CHROMOGENIC ASSAYS
3.5.3 NEXT-GENERATION SEQUENCING (NGS)
3.5.4 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP)
3.5.5 PORTABLE DNA SEQUENCER
3.5.6 NANOPIN DIAGNOSTIC PLATFORM
3.5.7 LUMINEX XMAP TECHNOLOGY
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 BARGAINING POWER OF SUPPLIERS
3.6.4 BARGAINING POWER OF BUYERS
3.6.5 COMPETITIVE RIVALRY
3.7 SUPPLY CHAIN ANALYSIS
3.8 REIMBURSEMENT SCENARIO
3.9 FUNDING SCENARIO
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10.1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.2 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.3 IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.10.4 POINT OF CARE (POC) DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.11 CORONAVIRUS (COVID-19)
3.12 FDA-EUA APPROVED DIAGNOSTICS TESTS
3.13 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TRANSMISSION
3.14 INFECTIOUS DISEASE DIAGNOSTICS COMPANY COMPARISON TABLE BY APPLICATION, SOURCE, TECHNOLOGY
4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 CONSUMABLES
4.3 INSTRUMENTS
4.4 SOFTWARE & SERVICES
5 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 IDD MOLECULAR DIAGNOSTICS
5.2.1 POLYMERASE CHAIN REACTION (PCR)
5.2.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
5.2.3 MICROARRAY
5.2.4 NEXT-GENERATION SEQUENCING (NGS)
5.2.5 IN-SITU HYBRIDIZATION (ISH)
5.2.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
5.3 IDD IMMUNO DIAGNOSTICS
5.3.1 CHEMILUMINESCENCE IMMUNOASSAY (CHLIA)
5.3.2 LATERAL FLOW IMMUNOCHROMATOGRAPHY ASSAY (LFIA)
5.3.3 ENZYME IMMUNOASSAY (EIA)
5.3.4 FLUORESCENT IMMUNOASSAY (FIA)
5.3.5 OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES
5.4 IDD OTHER DIAGNOSTICS
6 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 BACTERIAL INFECTION
6.2.1 TREPONEMA PALLIDUM
6.2.2 GARDNERELLA VAGINALIS
6.2.3 STAPHYLOCOCCUS AUREUS
6.2.4 CLOSTRIDIUM DIFFICILE
6.2.5 STREPTOCOCCUS (A & B)
6.2.6 METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
6.2.7 CHLAMYDIA TRACHOMATIS (CT) AND NEISSERIA GONORRHOEAE (NG)
6.2.8 TUBERCULOSIS (TB)
6.2.9 OTHER BACTERIAL INFECTION
6.3 VIRAL INFECTION
6.3.1 HIV-1
6.3.2 INFLUENZA
6.3.3 DENGUE
6.3.4 HEPATITIS B
6.3.5 HEPATITIS C
6.3.6 HUMAN PAPILLOMAVIRUS (HPV)
6.3.7 HERPES SIMPLEX VIRUS (HSV)
6.3.8 ZIKA VIRUS
6.3.9 OTHER VIRAL INFECTION
6.4 FUNGAL INFECTION
6.4.1 CANDIDA
6.4.2 ASPERGILLUS
6.4.3 OTHER FUNGAL INFECTION
6.5 OTHER INFECTION
6.5.1 MALARIA
6.5.2 TRICHOMONAS VAGINALIS
6.5.3 OTHER INFECTIONS
7 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY END-USER
7.1 INTRODUCTION
7.2 HOSPITAL, AMBULATORY SURGICAL CENTERS (ASCS) & CLINICS
7.3 CENTRALIZED LABORATORIES AND CLINICAL TRIALS
7.4 ACADEMICS AND RESEARCH INSTITUTES
7.5 OTHER END-USERS
8 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TESTING
8.1 INTRODUCTION
8.2 CENTRALIZED LABORATORIES
8.3 POINT OF CARE
9 REGIONAL ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 REST OF NORTH AMERICA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 ITALY
9.3.4 REST OF EUROPE
9.4 APAC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF APAC
9.5 ROW
9.5.1 BRAZIL
9.5.2 REST OF LATAM
9.5.3 MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 PRODUCT APPROVAL
10.3 NEW PRODUCT LAUNCH
10.4 OTHERS
11 MAJOR COMPANIES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BECTON, DICKINSON AND COMPANY
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIOMERIEUX SA
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 BIO-RAD LABORATORIES, INC.
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 DANAHER CORPORATION
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 F. HOFFMANN-LA ROCHE LTD
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 HOLOGIC, INC.
11.7.1 COVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 QIAGEN N.V.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 SIEMENS HEALTHINEERS GMBH
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 THERMO FISHER SCIENTIFIC INC.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 2 NUMBER OF CORONAVIRUS DIAGNOSTICS TEST KIT GLOBAL MARKET, BY REGION, (2020-2027) (NO’S)
TABLE 3 CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
TABLE 4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 5 CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 6 INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 7 SOFTWARE & SERVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 9 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 11 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 12 PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 13 INAAT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 14 MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 15 NGS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 16 ISH GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 17 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 20 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 CHLIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 LFIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 23 ENZYME IMMUNOASSAY (EIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 24 FLUORESCENT IMMUNOASSAY (FIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 25 OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 IDD OTHER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 28 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 29 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 30 TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 31 GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 32 STAPHYLOCOCCUS AUREUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 33 CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 34 STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 35 MRSA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 36 CT AND NG GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 37 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 38 OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 39 VIRAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 40 VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 41 HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 42 INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 43 DENGUE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 44 HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 45 HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 46 HPV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 47 HSV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 48 ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 49 OTHER VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 50 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 51 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 52 CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 53 ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 54 OTHER FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 55 OTHER INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 56 OTHER INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 57 MALARIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 58 TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 59 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 61 HOSPITAL, ASCS & CLINICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 62 CENTRALIZED LABORATORY AND CLINICAL TRIALS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 63 ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 64 OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 66 CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 67 POINT OF CARE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 68 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 69 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 70 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 71 NORTH AMERICA IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 72 NORTH AMERICA IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 73 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 74 NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 75 NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 76 NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 77 NORTH AMERICA OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 78 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 79 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 80 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 81 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 82 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 83 EUROPE IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 84 EUROPE IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 85 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 86 EUROPE BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 87 EUROPE VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 88 EUROPE FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 89 EUROPE OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 90 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 91 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 92 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 93 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 94 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 95 APAC IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 96 APAC IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 97 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 98 APAC BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 99 APAC VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 100 APAC FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 101 APAC OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 102 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 103 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 104 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 105 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 106 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 107 ROW IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 108 ROW IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 109 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 110 ROW BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 111 ROW VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 112 ROW FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 113 ROW OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 114 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 115 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TEST, (2019-2027) ($MN)
TABLE 116 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 117 PRODUCT LAUNCH (2018-2020)
TABLE 118 NEW PRODUCT LAUNCH (2018-2020)
TABLE 119 OTHERS (2018-2020)
TABLE 120 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 121 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 122 ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENT, (2018-2020) ($MN)
TABLE 123 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 124 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 125 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2019-2020) ($MN)
TABLE 126 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFESCIENCES SUB-SEGMENT, (2018-2020) ($MN)
TABLE 127 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 128 BIOMERIEUX SA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 129 BIOMERIEUX SA: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 130 BIOMERIEUX SA:TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 131 BIO-RAD LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 132 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 133 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 134 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 135 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 136 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 137 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 138 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 139 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 140 HOLOGIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 141 HOLOGIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 142 HOLOGIC, INC.: DIAGNOSIS REVENUE, BY SUB-SEGMENT, (2018-2020) ($MN)
TABLE 143 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 144 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 145 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 146 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 147 SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 148 SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 149 SIEMENS HEALTHINEERS GMBH.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 150 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 151 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 152 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 2 NUMBER OF CORONAVIRUS DIAGNOSTICS TEST KIT GLOBAL MARKET, BY REGION, (2020-2027) (NO’S)
TABLE 3 CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
TABLE 4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 5 CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 6 INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 7 SOFTWARE & SERVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 9 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 11 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 12 PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 13 INAAT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 14 MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 15 NGS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 16 ISH GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 17 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 20 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 CHLIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 LFIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 23 ENZYME IMMUNOASSAY (EIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 24 FLUORESCENT IMMUNOASSAY (FIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 25 OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 IDD OTHER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 28 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 29 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 30 TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 31 GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 32 STAPHYLOCOCCUS AUREUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 33 CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 34 STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 35 MRSA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 36 CT AND NG GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 37 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 38 OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 39 VIRAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 40 VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 41 HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 42 INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 43 DENGUE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 44 HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 45 HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 46 HPV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 47 HSV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 48 ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 49 OTHER VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 50 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 51 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 52 CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 53 ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 54 OTHER FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 55 OTHER INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 56 OTHER INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 57 MALARIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 58 TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 59 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 61 HOSPITAL, ASCS & CLINICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 62 CENTRALIZED LABORATORY AND CLINICAL TRIALS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 63 ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 64 OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 66 CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 67 POINT OF CARE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 68 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 69 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 70 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 71 NORTH AMERICA IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 72 NORTH AMERICA IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 73 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 74 NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 75 NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 76 NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 77 NORTH AMERICA OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 78 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 79 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 80 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 81 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 82 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 83 EUROPE IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 84 EUROPE IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 85 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 86 EUROPE BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 87 EUROPE VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 88 EUROPE FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 89 EUROPE OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 90 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 91 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 92 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 93 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 94 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 95 APAC IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 96 APAC IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 97 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 98 APAC BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 99 APAC VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 100 APAC FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 101 APAC OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 102 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 103 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
TABLE 104 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 105 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 106 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
TABLE 107 ROW IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 108 ROW IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
TABLE 109 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 110 ROW BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 111 ROW VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 112 ROW FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 113 ROW OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
TABLE 114 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
TABLE 115 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TEST, (2019-2027) ($MN)
TABLE 116 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 117 PRODUCT LAUNCH (2018-2020)
TABLE 118 NEW PRODUCT LAUNCH (2018-2020)
TABLE 119 OTHERS (2018-2020)
TABLE 120 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 121 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 122 ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENT, (2018-2020) ($MN)
TABLE 123 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 124 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 125 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2019-2020) ($MN)
TABLE 126 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFESCIENCES SUB-SEGMENT, (2018-2020) ($MN)
TABLE 127 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 128 BIOMERIEUX SA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 129 BIOMERIEUX SA: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 130 BIOMERIEUX SA:TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 131 BIO-RAD LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 132 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 133 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 134 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 135 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 136 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 137 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 138 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 139 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 140 HOLOGIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 141 HOLOGIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 142 HOLOGIC, INC.: DIAGNOSIS REVENUE, BY SUB-SEGMENT, (2018-2020) ($MN)
TABLE 143 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 144 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 145 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 146 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 147 SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 148 SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 149 SIEMENS HEALTHINEERS GMBH.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 150 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 151 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 152 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
LIST OF FIGURES
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET
FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION BY APPLICATION AND REGION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 12 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 13 IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 14 POINT OF CARE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 15 CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 16 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 17 CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2020 V/S 2027) (%)
FIGURE 19 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 20 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 21 INAAT GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 22 MICROARRAY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 23 ISH GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 24 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 25 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 27 BACTERIAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
FIGURE 28 TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 29 STAPHYLOCOCCUS AUREUS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 30 CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 31 STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 32 MRSA GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 33 CT AND NG GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 34 OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 35 VIRAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 36 VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 37 FUNGAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
FIGURE 38 OTHER INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 40 HOSPITAL, ASCS & CLINICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 41 CENTRALIZED LABORATORIES AND CLINICAL TRIALS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 42 OTHER END-USERS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 43 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY MODE OF TESTING (2020 V/S 2027) (%)
FIGURE 44 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
FIGURE 45 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
FIGURE 46 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 47 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 48 NORTH AMERICA BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 49 NORTH AMERICA VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 50 NORTH AMERICA FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 51 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 52 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 53 U.S. INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 54 REST OF NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 55 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 56 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 57 EUROPE BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 58 EUROPE VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 59 EUROPE FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 60 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 61 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 62 GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 63 FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 64 ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 65 REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 66 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 67 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 68 APAC BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 69 APAC VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 70 APAC FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 71 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 72 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 73 JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 74 CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 75 INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 76 REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 77 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 78 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 79 ROW BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 80 ROW VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 81 ROW FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 82 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 83 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 84 BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 85 REST OF LATAM INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 86 MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 87 KEY GROWTH STRATEGIES, (2018-2020)
FIGURE 88 SWOT: ABBOTT LABORATORIES
FIGURE 89 SWOT: BECTON, DICKINSON AND COMPANY
FIGURE 90 SWOT: BIOMERIEUX SA
FIGURE 91 SWOT: BIO-RAD LABORATORIES, INC.
FIGURE 92 SWOT: DANAHER CORPORATION
FIGURE 93 SWOT: F.HOFFMANN-LA ROCHE LTD.
FIGURE 94 SWOT: HOLOGIC, INC.
FIGURE 95 SWOT: QIAGEN N.V
FIGURE 96 SWOT: SIEMENS HEALTHINEERS GMBH
FIGURE 97 SWOT: THERMO FISHER SCIENTIFIC INC.
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET
FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION BY APPLICATION AND REGION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 12 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 13 IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 14 POINT OF CARE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 15 CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 16 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 17 CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2020 V/S 2027) (%)
FIGURE 19 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 20 IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 21 INAAT GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 22 MICROARRAY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 23 ISH GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 24 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 25 IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 27 BACTERIAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
FIGURE 28 TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 29 STAPHYLOCOCCUS AUREUS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 30 CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 31 STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 32 MRSA GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 33 CT AND NG GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 34 OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 35 VIRAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 36 VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 37 FUNGAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
FIGURE 38 OTHER INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 40 HOSPITAL, ASCS & CLINICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 41 CENTRALIZED LABORATORIES AND CLINICAL TRIALS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 42 OTHER END-USERS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 43 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY MODE OF TESTING (2020 V/S 2027) (%)
FIGURE 44 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
FIGURE 45 INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
FIGURE 46 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 47 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 48 NORTH AMERICA BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 49 NORTH AMERICA VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 50 NORTH AMERICA FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 51 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 52 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 53 U.S. INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 54 REST OF NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 55 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 56 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 57 EUROPE BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 58 EUROPE VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 59 EUROPE FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 60 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 61 EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 62 GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 63 FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 64 ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 65 REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 66 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 67 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 68 APAC BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 69 APAC VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 70 APAC FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 71 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 72 APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 73 JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 74 CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 75 INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 76 REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 77 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
FIGURE 78 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 79 ROW BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 80 ROW VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 81 ROW FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
FIGURE 82 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
FIGURE 83 ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 84 BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 85 REST OF LATAM INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 86 MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
FIGURE 87 KEY GROWTH STRATEGIES, (2018-2020)
FIGURE 88 SWOT: ABBOTT LABORATORIES
FIGURE 89 SWOT: BECTON, DICKINSON AND COMPANY
FIGURE 90 SWOT: BIOMERIEUX SA
FIGURE 91 SWOT: BIO-RAD LABORATORIES, INC.
FIGURE 92 SWOT: DANAHER CORPORATION
FIGURE 93 SWOT: F.HOFFMANN-LA ROCHE LTD.
FIGURE 94 SWOT: HOLOGIC, INC.
FIGURE 95 SWOT: QIAGEN N.V
FIGURE 96 SWOT: SIEMENS HEALTHINEERS GMBH
FIGURE 97 SWOT: THERMO FISHER SCIENTIFIC INC.
